Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung Cancer Provided January 17, 2024
TIVDAK® Supplemental BLA Accepted for Priority Review by FDA for Patients with Recurrent or Metastatic Cervical Cancer January 17, 2024
Update on Zolbetuximab Biologics License Application in U.S.: FDA rejects the application January 17, 2024
European Commission Approves KRAZATI (adagrasib) for Patients with Advanced NSCLC with a KRASG12C Mutation January 17, 2024
FDA Approves KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy as Treatment for Patients With FIGO 2014 Stage III-IVA Cervical Cancer January 17, 2024
